EREG and cancer: Interestingly, in non-basal and TKI resistant cancer cells (J82), inhibition of EGFR phosphorylation mediated by erlotinib was associated with increased mRNA expression of EGFR (FC: 44.6), ERBB3 (FC: 92.3) and EREG (FC: 3.5).